Axial Spondyloarthritis (axSpA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Axial Spondyloarthritis, a chronic autoinflammatory disorder of the sacroiliac joints and spine, causes can occur with symptoms like fatigue, spinal pain, arthralgia (joint pain) or swelling, enthesitis (inflammation of the entheses), and morning stiffness. There are millions of diagnosed prevalent cases of axial Spondyloarthritis worldwide.
The Axial Spondyloarthritis marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, late-stage pipeline products with phase transition success rate (PTSR), and likelihood of approval (LoA) for axSpA. The report also analyzes the clinical and commercial landscapes of axSpA, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
Leading Marketed Drugs for Axial Spondyloarthritis
Adalimumab, Etanercept, Golimumab, Ixekizumab, and Upadacitinib are some of the primary drugs for Axial Spondyloarthritis. AbbVie – Humira, Novartis – Cosentyx, and Pfizer – Enbrel are some of the key brands involved in the production of leading marketed drugs in Axial Spondyloarthritis.
Axial Spondyloarthritis Marketed Drugs Segmentation by Mechanism of Action
The majority of marketed drugs for Axial Spondyloarthritis are receptor agonists and enzyme inhibitors. Receptor antagonist, biological factor inhibitor, and ion channel blocker are some of the primary mechanisms of actions in the marketed drugs for Axial Spondyloarthritis.
Axial Spondyloarthritis Marketed Drugs Analysis, by Mechanism of Action, 2022 (%)
For more MoA insights into the Axial Spondyloarthritis marketed drugs, download a free report sample
Axial Spondyloarthritis Marketed Drugs Segmentation by Molecule Type
The majority of the marketed drugs for Axial Spondyloarthritis are small molecules. Biologic is another significant molecule type in the marketed drugs for Axial Spondyloarthritis.
Axial Spondyloarthritis Marketed Drugs Analysis, by Molecule type, 2022 (%)
For more molecule type insights into the Axial Spondyloarthritis marketed drugs, download a free report sample
Axial Spondyloarthritis Marketed Drugs Segmentation by Routes of Administration
More than half of the marketed drugs for Axial Spondyloarthritis utilize an oral route of administration. The other four RoA in the marketed drugs for Axial Spondyloarthritis are injection, inhalational, topical, and suppository.
Axial Spondyloarthritis Marketed Drugs Analysis, by Routes of Administration, 2022 (%)
For more RoA insights into the Axial Spondyloarthritis marketed drugs, download a free report sample
Leading Pipeline Drugs for Axial Spondyloarthritis
In the current axSpA late-stage clinical development, drugs are targeting IL-17A or IL-17A/F and JAK1, with biosimilars for anti-TNF agents also in the pipeline. Upadacitinib ER, Adalimumab biosimilar, and Brodalumab are some of the primary pipeline drugs for Axial Spondyloarthritis.
Axial Spondyloarthritis Pipeline Drugs Segmentation by Mechanism of Action
Most of the pipeline drugs undergoing development for axSpA with a known mechanism of action are biological factor inhibitors. Receptor antagonists, enzyme inhibitors, and receptor agonists are other significant mechanisms of action in the axSpA pipeline drugs.
Axial Spondyloarthritis Pipeline Drugs Analysis, by Mechanisms of Action, 2022 (%)
For more MoA insights into the Axial Spondyloarthritis pipeline drugs, download a free report sample
Axial Spondyloarthritis Pipeline Drugs Segmentation by Molecule Type
Currently the majority of drugs in various development stages are biologics. Small molecule and Oligonucleotide are the other two molecule types found in pipeline drugs in Axial Spondyloarthritis.
Axial Spondyloarthritis Pipeline Drugs Analysis, by Molecule Types, 2022 (%)
For more molecule type insights into the Axial Spondyloarthritis pipeline drugs, download a free report sample
Axial Spondyloarthritis Pipeline Drugs Segmentation by Routes of Administration
Of the pipeline drugs undergoing development for Axial Spondyloarthritis with a known route of administration, injectable, topical, and oral therapies are all common. Majority of the Axial Spondyloarthritis pipeline drugs are injectables.
Axial Spondyloarthritis Pipeline Drugs Analysis, by Routes of Administration, 2022 (%)
For more RoA insights into the Axial Spondyloarthritis pipeline drugs, download a free report sample
Top Sponsors in the Axial Spondyloarthritis Marketed and Pipeline Drugs Market
Novartis has sponsored the highest number of clinical trials of all the clinical trials in Axial Spondyloarthritis that were initiated over the past 10 years. UCB SA, Pfizer Inc, and Biocad are some of the top sponsors in the clinical trials of Axial Spondyloarthritis marketed and pipeline drugs market.
Axial Spondyloarthritis Marketed Drugs Report Overview
Key Mechanisms of Action (Marketed Drugs) | Receptor Agonist, Receptor Antagonist, Enzyme Inhibitor, Biological Factor Inhibitor, and Ion Channel Blocker |
Analysis Year | 2022 |
Key Routes of Administration (Marketed Drugs) | Injections, Oral, Topical, Inhalational, And Suppository |
Key Molecule Types (Marketed Drugs) | Small Molecule, and Biologic |
Axial Spondyloarthritis Pipeline Drugs Market Report Overview
Key Mechanisms of Action (Pipeline Drugs) | Receptor Antagonists, Biological Factor Inhibitors, Enzyme Inhibitors, and Receptor Agonists |
Analysis Year | 2022 |
Key Routes of Administration (Pipeline Drugs) | Injection, Topical, and Oral |
Key Molecule Types (Pipeline Drugs) | Small Molecule, Oligonucleotide, and Biologic |
Top Sponsors | Novartis, UCB SA, Pfizer Inc, and Biocad |
Axial Spondyloarthritis Marketed Drugs Market MoA Overview ( No of Drugs in the Pipeline, 2022)
- Axial Spondyloarthritis Marketed Drugs Market MoA Overview ( No of Drugs in the Pipeline, 2022)
Axial Spondyloarthritis Marketed Drugs Market RoA Overview ( No of Drugs in the Pipeline, 2022)
- Injections
- Oral
- Topical
- Inhalational
- Suppository
Axial Spondyloarthritis Marketed Drugs Market Molecule Types Overview ( No of Drugs in the Pipeline, 2022)
- Small Molecule
- Biologic
Axial Spondyloarthritis Pipeline Drugs Market MoA Overview ( No of Drugs in the Pipeline, 2022)
- Receptor Antagonists
- Biological Factor Inhibitors
- Enzyme Inhibitors
- Receptor Agonists
Axial Spondyloarthritis Pipeline Drugs Market RoA Overview ( No of Drugs in the Pipeline, 2022)
- Injection
- Topical
- Oral
Axial Spondyloarthritis Pipeline Drugs Market Molecule Types Overview ( No of Drugs in the Pipeline, 2022)
- Small Molecule
- Oligonucleotide
- Biologic
Scope
GlobalData’s “Axial Spondyloarthritis (axSpA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape” combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the axSpA market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global axSpA market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action for Axial Spondyloarthritis marketed drugs?
The key mechanisms of action for Axial Spondyloarthritis marketed drugs are receptor agonist, receptor antagonist, enzyme inhibitor, biological factor inhibitor, and ion channel blocker.
-
What are the key routes of administration for Axial Spondyloarthritis marketed drugs?
The key routes of administration for Axial Spondyloarthritis marketed drugs are injections, oral, topical, inhalational, and suppository.
-
What are the key molecule types for Axial Spondyloarthritis marketed drugs?
The key molecule types for Axial Spondyloarthritis marketed drugs are small molecule, and biologic.
-
What are the key mechanisms of action for Axial Spondyloarthritis pipeline drugs?
The key mechanisms of action for Axial Spondyloarthritis pipeline drugs market are receptor antagonists, biological factor inhibitors, enzyme inhibitors, and receptor agonists.
-
What are the key routes of administration for Axial Spondyloarthritis pipeline drugs?
The key routes of administration for Axial Spondyloarthritis pipeline drugs market are injection, topical, and oral.
-
What are the key molecule types for Axial Spondyloarthritis pipeline drugs?
The key molecule types in the Axial Spondyloarthritis pipeline drugs market are small molecule, oligonucleotide, and biologic.
-
Who are the top sponsors for the Axial Spondyloarthritis marketed and pipeline drugs market?
Some of the top sponsors in the Axial Spondyloarthritis marketed and pipeline drugs market are Novartis, UCB SA, Pfizer Inc, and Biocad.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.